John D Quisel sold $2.6M of IRON
Chief Executive Officer at Disc Medicine, Inc.. 33,000 shares at an average of $79.15, traded Aug 17, 2026, filed Aug 18, 2026.
Score components
- +25RoleCEO
- +25Trade size$2.6M at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-355841, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | MOption exercise Common Stock10b5-1 | +33,000 | $13.50 | $446k | 259,064 | Aug 18, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock10b5-1 | -8,400 | $78.11 | $656k | 250,664 | Aug 18, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock10b5-1 | -12,712 | $79.20 | $1.0M | 237,952 | Aug 18, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock10b5-1 | -11,888 | $79.84 | $949k | 226,064 | Aug 18, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -33,000 | $0.00 | $0 | 91,586 | Aug 18, 2026 |
Related signals
Other insiders at Disc Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRONsell Disc Medicine, Inc. | Kevin Bitterman director | $1.9M 27,136 shares | -100% | |
| 14Weak | Disc Medicine, Inc. | Kevin Bitterman director | $135k 1,689 shares | -1% | |
| 33Weak | Disc Medicine, Inc. | Kevin Bitterman director | $4.4M 54,496 shares | -16% | |
| 27Weak | Disc Medicine, Inc. | Jonathan Yen-Wen Yu Chief Operating Officer | $756k 9,096 shares | -17% | |
| 8Weak | Disc Medicine, Inc. | Jonathan Yen-Wen Yu Chief Operating Officer | $66k 804 shares | -1% | |
| 11Weak | Disc Medicine, Inc. | Rahul Khara Chief Legal Officer | $400k 5,000 shares | -9% | |
| 28Weak | Disc Medicine, Inc. | John D Quisel Chief Executive Officer | $2.5M 33,000 shares | -13% | |
| 0Weak | Disc Medicine, Inc. | Jonathan Yen-Wen Yu Chief Operating Officer | $8,250 100 shares | -0% | |
| 0Weak | Disc Medicine, Inc. | Jonathan Yen-Wen Yu Chief Operating Officer | $22k 300 shares | -1% | |
| 7Weak | Disc Medicine, Inc. | Rahul Khara Chief Legal Officer | $188k 2,500 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.